wilate - Simple, Convenient and Proven Effective in VWD Treatment

wilate has low recommended loading and maintenance dosing for all VWD types 1*

Minor Hemorrhages

Loading dosage
(IU VWF:RCo/kg BW)
Maintenance dosage
(IU VWF:RCo/kg BW)
Therapeutic goal
20-40 IU/kg20-30 IU/kg
every 12-24 hours*
VWF:RCo and FVIII activity trough levels of >30%

Major Hemorrhages

Loading dosage
(IU VWF:RCo/kg BW)
Maintenance dosage
(IU VWF:RCo/kg BW)
Therapeutic goal
40-60 IU/kg20-40 IU/kg
every 12-24 hours*
VWF:RCo and FVIII activity trough levels of >50%
RCo=ristocetin cofactor; BW=bodyweight.
*This may need to be continued for up to 3 days for minor hemorrhages and 5 to 7 days for major hemorrhages.
*Based on the Recommended Dosing Guide for wilate. See Dosage and Administration, section 2.1 of full Prescribing Information.

Humate-P® is a VWF/FVIII complex for the treatment of VWD with recommended loading dose ranges that are typically higher than wilate, and recommended maintenance dose intervals that are typically shorter.

Humate-P® VWF:RCo dosing recommendations for the treatment of bleeding episodes by VWD type2

Type 1 VWD – Mild (baseline VWF:Rco activity typically>30%)

Severity of HemorrhageDosage (IU VWF:RCo/kg BW)
Minor
(eg, epistaxis, oral bleeding, menorrhagia)
Typically treatable with desmopressin.
Minor
(when desmonpressin is known or suspected to be inadequate)Major
(eg, severe or refractory epistaxus, GI bleeding, CNS trauma, traumatic hemorrhage)
Loading dose 40-60 IU/kg.
Then 40-50 IU/kg every 8-12 hours for 3 days to keep the trough level of VWF:RCo>50%.Then 40-50 IU/kg daily for up to 7 days.

Type 1 VWD – Moderate or severe (baseline VWF:Rco activity typically<30%)

Severity of HemorrhageDosage (IU VWF:RCo/kg BW)
Minor
(eg, epistaxis, oral bleeding, menorrhagia)
40-50 IU/kg (1 or 2 doses)
Major
(eg, severe or refractory epistaxis, GI bleeding, CNS trauma, hearmathrosis, traumatic hemorrhage)
Loading dose 50-75 IU/kg
Then 40-60 IU/kg every 8-12 hours for 3 days to keep the trough level of VWF:RCo>50%Then 40-60 IU/kg daily for up to 7 days.

Type 2 VWD (all variants) and Type 3 VWD

Severity of HemorrhageDosage (IU VWF:RCo/kg BW)
Minor
(clinical indications above)
40-50 IU/kg (1 or 2 doses)
Major
(clinical indications above)
Loading dose 60-80 IU/kg.
Then 40-50 IU/kg every 8-12 hours for 3 days to keep the trough level of VWF:RCo>50%.
Then 40-60 IU/kg daily for up to 7 days.
GI=gastrointestinal; CNS=central nervous system

*Presentation of Humate-P® dosing information is not intended to claim or imply equivalence to wilate in efficacy, safety, or other conditions of use.

*For major bleeds in all types of VWD where repeated dosing is required, monitor and maintain the patient’s FVIII level according to the guidelines for hemophilia A therapy.

Humate-P® is manufactured by and is a registered trademark of CSL Behring.

Vial Sizes
500 IU VWF:RCo and 500 IU FVIII activities in 5 ml
1000 IU VWF:RCo and 500 IU FVIII activities in 10 ml
  • Store wilate up to 36 months in a refrigerator at +2°C to +8°C (36°F to 46°F) protected from light from the date of manufacture
  • Within this period, wilate may be stored up to 6 months at room temperature (maximum of +25°C or 77°F). Once stored at room temperature, the product must not be returned to the refrigerator.
cta circles background
5ec8538b9d38f1b8cf12e0c74b344bf8 Created with Sketch.

See instructional video on how to reconstitute and infuse wilate.

Watch now

References
  1. wilate Full prescribing information. Hoboken, NJ: Octapharma; rev 2015.
  2. Humate-P® Full Prescribing Information. Kankakee, IL: CSL Behring; September 2016.